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obtained from Ministry of Health Drug Price List, Price List of
Social Security Institution Health Implementation Guideline
Appendix 2/D and 8, respectively. Clinical and economic out-
comes: The clinical outcome measure is the proportion of
patients responding. The model takes into consideration all of
direct costs associated with the treatment, i.e. antifungal medi-
cations, treatment of side effects and tests. Because the time
horizon of the model is shorter than 1-year, costs are not
discounted. RESULTS: Total costs and response rates are
€2,560/0.40, €8.900/0.47 and €3.790/0.32 for itraconazole,
voriconazole and amphotericin-B, respectively. When compared
with amphotericin-B, additional response rate that is gained
with itraconazole is 0.08. This gain is obtained with €1230 less
cost. Incremental response rate that is gained with voriconazole
is 0.07. This gain is obtained with €6,350 extra cost, i.e. in-
cremental cost-effectiveness ratio (ICER) is €91,000/response.
One-way sensitivity analyses prove that results of the study are
strong. CONCLUSIONS: In the treatment of aspersillosis,
itraconazole is the dominant therapy in comparison to
amphotericine-B. Compared to voriconazole, itraconazole is the
cost-effective therapy option with the ICER of €82,800/
response for voriconazole.
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OBJECTIVES: Since mortality rate due to invasive fungal infec-
tions (IFI) associated with febrile neutropenia (FN) is very high,
empirical antifungal treatment is the mainstay of treatment in
patients with FN. The aim of the study is to compare the cost-
effectiveness of parenteral itraconazole with amphotericin-B
in empirical treatment of IFIs in cancer patients with FN.
METHODS: Model: Decision tree modeling is used in the cal-
culation of cost-effectiveness of options. The time horizon con-
sidered in the model is 20 days. The study has been performed
from the health care payer perspective. Patient group: Cancer
patients older than 18 years, with persistent fever despite anti-
infective treatment. Data sources: The clinical data are acquired
from published clinical studies. Resource use data are based on
expert panel. Prices of medications, institutional discount rates
and other costs related to the treatment obtained from Ministry
of Health Drug Price List, Price List of Social Security Institu-
tion Health Implementation Guideline Appendix 2/D and 8.
Clinical and economic outcomes: Clinical outcome is response
to the treatment. Direct medical costs that are considered are
the costs related with antifungal treatment and side effects.
Because the time horizon of the model is shorter than 1 year,
costs are not discounted. The results are presented as additional
cost per additional response (ICER). Number-needed-to-treat
(NNT) values are also calculated. RESULTS: Response rates
are 0.59 and 0.61, and total costs are €2460 and €2773for
itraconazole and amphotericin-B, respectively. ICER is calcu-
lated as €14.898/response rate for amphotericin-B. NNT values
are 1.69 and 1.64 for itraconazole and amphotericin-B, respec-
tively. A total of €390 will be saved for equal clinical outcome,
if itraconazole is used instead of amphotericin-B. One-way sen-
sitivity analyses prove that the results of the study are strong.
CONCLUSIONS: Itraconazole is a cost-effective treatment
modality in the empirical treatment of IFIs in FN patients in
Turkey.
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OBJECTIVES: Facial lipoatrophy is a signiﬁcant problem related
to antiretroviral therapy for people living with HIV. The only
intervention currently available is the surgical correction with
facial ﬁllers. Objective of this study was to evaluate efﬁcacy and
efﬁciency of injection of various ﬁllers: 1) poly-L-lactid acid; 2)
polyacrylamide hydrogel; and 3) hyaluronic acid + tricalcium
phosphate. METHODS: Cost-effectiveness analysis (CEA) was
performed on the results of a randomized controlled clinical trial
comparing a surgical correction of lipoatrophy versus the usual
clinical care without intervention, over six-month follow-up.
Clinical information was collected with the facial lipoatrophy
scale (possible score 0 = normal, to 3 = severe lipodystrophy).
Direct costs (costs of surgeon, ﬁllers, chirurgical instruments)
were evaluated from the service supplier’s perspective in Italy and
analysed according to prices and tariffs applied in 2008. Data
from 67 patients per arm were collected at baseline and at 0–6
time points. RESULTS: Lipoﬁlling intervention resulted in a
lipoatrophy improvement, with a mean  SD change in facial
lipoatrophy scale of -3.0  0.9. To implement this surgical pro-
cedure, service supplier should sustain an overall cost mean cost
of €2126.42 per patient, corresponding to an incremental cost-
effectiveness ratio of €708.66 per unit of improved facial lipoat-
rophy. CONCLUSIONS: According to preliminary results,
lipoﬁlling intervention for lipoatrophy in HIV patients is cost-
effective: to obtain a decrease of one grade of lipoatrophy, a cost
of €708.66 is expected to be sustained. Information obtained
with this study, can be helpful to make appropriate decisions for
the provision of optimal health care for these patients.
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OBJECTIVES: To perform economical evaluation of etravirine
(ETR) in treatment-experienced HIV-1-infected patients in
Russian health care system. METHODS: The modeled study was
performed. Multicenter randomized studies DUET 1 and 2 were
used as a basis for the model. Cost-effectiveness of ETR com-
pared to placebo, both given with a background regimen (BR) of
nucleoside reverse transcriptase inhibitors, darunavir/ritonavir
and optional enfuvirtide, was assessed. Costs of antiretroviral
therapy for 24 weeks were calculated from the point of Russian
health care system view. Proportion of patients receiving different
drugs and dosing regimen were extracted from DUET 1 and 2
trials. Effect was measured in proportion of patients with viral
load less than 50 copies/ml. Limitation of the model was that
emtricitabine and tenofovir used in BR in both groups have no
market authorization in Russia and were excluded from the
model. Similar proportion of patients in both groups received
these drugs, thus this limitation did not inﬂuence the incremental
cost-effectiveness ratio (ICER). One-way sensitivity analysis was
performed. RESULTS: According to DUET studies ETR was
much more effective than placebo (59 vs 41% patients achieved
viral load <50 copies/ml, p < 0,001), while cost of treatment
(without emtricitabine and tenofovir) was more for ETR than
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placebo group (difference in cost 4247,36 USD). Incremental
CER was 20 360,90 USD for one patient with viral load <50
copies/ml (16 462,65–41 640,81 USD in sensitivity analysis).
Cost of one patient with achieved viral load <50 copies/ml was
lower for ETR group. CONCLUSIONS: According to the model
ETR seems to be much more effective than placebo with afford-
able CER incremental ratio. Evaluation of ETR treatment cost-
effectiveness in common practice in Russian health care is
needed.
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OBJECTIVES: It is estimated that annually 300,000 cases of
rotavirus-induced gastroenteritis (RVGE) occur in children aged
up to 5 years in France. RIX4414 (Rotarix™ GlaxoSmith-
Kline), a two-dose oral vaccine against rotavirus infection, has
been shown to be highly effective against severe RVGE. A
recent study (Melliez et al, Vaccine 2008) concluded that
rotavirus vaccination was not cost-effective according to French
Public Health context. We evaluated the cost-effectiveness of
general vaccination against rotavirus using Rotarix™ in France
using an updated model. We investigated the differences in
modelling approaches and resultant cost-effectiveness conclu-
sions. METHODS: A Markov model simulated RVGE events
and the associated outcomes and costs in a birth cohort of
children in France (n = 750,000), adjusting for age distribution
and seasonality of infection. Costs and outcomes were esti-
mated from a limited societal perspective (without indirect
costs). The primary outcome measure was the incremental cost
per quality-adjusted life year (QALY). RESULTS: Vaccination
with Rotarix™ incurred an incremental cost of €44,583/QALY
at a public price of €57 per vaccine dose. Univariate sensitivity
analyses showed that the results were largely inﬂuenced by the
discount rate for beneﬁts, nosocomial rotavirus infection
burden, hospital costs, and vaccine efﬁcacy and cost. The
acceptability curve indicated that 60% of the results were
under the threshold of €50,000/QALY. Comparing these results
with those of Melliez et al, the apparent discrepancy can be
largely explained by differences in model structure and data
input values including: different at-risk period and time
horizon; different vaccine efﬁcacy; different unit cost data; dif-
ferent disease duration and disutility values. CONCLUSIONS:
These results demonstrate that a generalized vaccination strat-
egy with Rotarix™ would be cost-effective in France from a
societal perspective without including indirect costs; however
there is a need for agreed standards to improve comparability
of results from different studies.
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OBJECTIVES: The aim of this study is to evaluate the long-
term economic cost-effectiveness and clinical impact of univer-
sal infant vaccination of 7-valent pneumococcal conjugate
vaccine (PCV7) in Taiwan by using a dynamic SIR model.
METHODS: Recently, there are lots of interests surrounding
the cost-effectiveness of PCV7 against pneumococcal diseases.
Particularly, the quantiﬁcation of the herd-immunity effects
caused by this vaccine has been widely discussed. A cohort
model in our previous study indicated that the universal PCV7
vaccination in Taiwan is a cost-effective intervention with
an incremental cost per life year gained of NT344,928
(US$11,227), preventing thousands of IPD cases over a 10-year
horizon. However, this model cannot dynamically capture age-
dependent force of infection associated with the effects of dif-
ferent contact patterns on pre- and post-vaccination. Hence, the
herd-immunity externalities cannot be correctly estimated,
which would bias our ﬁndings. To reassess the cost-effectiveness
of this vaccine, we incorporated a dynamic realistic age-
structured Susceptible-Infected-Recovered (SIR) model that can
account for both the direct and indirect (i.e. herd-immunity
effects) beneﬁts of vaccination. All pre-vaccination parameters
such as age-speciﬁc disease incidence, mortality, seroprevalence
data, and cost associated with the treatment of pneumococcal
diseases were obtained from the National Health Insurance
(NHI) Database and published literature where available. A
societal perspective and a health care payer’s perspective were
adopted. Various vaccine strategies including hypothetical sce-
narios were investigated. One-way and multi-way sensitivity
analyses were also performed to evaluate model robustness.
RESULTS: Our model suggests that universal PCV7 vaccina-
tion has a considerable impact on the reductions of the mor-
bidity and incidence related to pneumococcal diseases where
the herd-immunity effects are more precisely quantiﬁed using
dynamic SIR model. CONCLUSIONS: A universal infant vac-
cination with PCV7 is a cost-effective intervention from a
dynamic perspective and its continuous vaccination in Taiwan
is greatly encouraged.
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OBJECTIVES: The Phase III TITAN trial (TMC114-C214)
evaluated darunavir/ritonavir (DRV/r) 600/100 mg bid versus
lopinavir/ritonavir (LPV/r) 400/100 mg bid in treatment-ex-
perienced, LPV/r-naïve, HIV-infected adults. We determined the
cost-effectiveness of DRV/r versus LPV/r from the perspective of
British, Swedish, Italian and Belgian payers in the TITAN trial
subgroup with at least one IAS-USA primary protease inhibitor
(PI) mutation at baseline. These patients had less advanced HIV
disease and a broader degree of prior PI use/failure (0 = 2) than
those in the DRV Phase IIb POWER trials (= 2). METHODS: An
existing Markov model containing 6 CD4+ T-cell count (CD4
count)-deﬁned health states and a “death” state was adapted to
the abovementioned countries. Baseline demographics and CD4
count distribution, antiretroviral drug usage, virologic and
immunologic response rates and matching transition probabili-
ties were based on TITAN trial data collected in the modelled
subgroup during the ﬁrst 48 weeks of therapy and from pub-
lished literature. Patients were assumed to switch to a follow-up
combination therapy after failure. For each model state, utility
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